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Background: Starting lifelong antiretroviral therapy (ART) in HIV-
infected pregnant women may decrease HIV progression and trans-
mission, but adherence after delivery may be difficult, especially for
asymptomatic women. We evaluated disease progression among HIV-
infected women not on ART with CD4+ lymphocyte counts above 200
cells per microliter at delivery.
Methods: We analyzed risk of death, progression to AIDS (stage
IV or CD4 , 200 cells per microliter), or to CD4+ count ,350
1 year after delivery among postpartum women enrolled to a preven-
tion of breastfeeding transmission trial using the Kaplan–Meier
method. In the primary analysis, women were censored if ART
was initiated.
Results: Among 1285 women who were not WHO stage IV or less
at 6 weeks postpartum, 49 (4.3%) progressed to stage IV/CD4 ,200
cells per microliter or death by 1 year. Progression to CD4 ,200 cells
per microliter or death occurred among 16 (4.3%) of 441 women with
CD4 count of 350–549 cells per microliter and 10 (1.6%) of 713 with
CD4 counts.550 cells per microliter at delivery. CD4 ,350 cells per
microliter by 12 months postpartum occurred among 116 (37.0%) of
350 women with CD4 count 400–549 cells per microliter and 48
(7.4%) of 713 with CD4 count .550 cells per microliter at delivery.
Conclusions: Progression to AIDS or CD4 count ,350 cells per
microliter is uncommon through 1 year postpartum for women with
CD4 counts over 550 cells per microliter at delivery, but occurred in
over one third of those with CD4 counts under 550 cells per micro-
liter. ART should be continued after delivery or breastfeeding among
women with CD4 counts ,550 cells per microliter if follow-up and
antiretroviral adherence can be maintained.
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BACKGROUND
A recent World Health Organization (WHO) program-
matic update has suggested that all HIV-infected pregnant
women should be considered for initiation of triple antire-
troviral (ARV) regimens for prevention of mother-to-child
transmission with consideration given to continuing all
women on ARVs for life once initiated, regardless of starting
CD4+ lymphocyte count.1 The recommendation for use of
triple ARV regimens, rather than zidovudine alone during
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pregnancy with additional peripartum ARV drugs for women
with high CD4+ cell counts, is based on several considera-
tions. Rapid initiation of combination ARV drugs without
waiting for CD4 results in settings where CD4+ cell counts
are often delayed assures treatment for women with low
CD4+ lymphocyte counts who have the highest risk of trans-
mission.2 Using the same regimen for all pregnant women and
other adults allows for streamlining of drug supply and pro-
vider training. In addition, treating HIV-infected persons at
higher CD4+ cell counts resulted in lower risk of transmission
to sexual partners in a recent trial.3
However, the risks versus benefits of continuing triple
antiretroviral regimens started among generally healthy
asymptomatic pregnant women with higher CD4+ lympho-
cyte counts after delivery or cessation of breastfeeding have
not been evaluated adequately. The postpartum period is
known in both resource-rich and resource-poor settings to
be a high risk period for poor HIV treatment adherence, given
the demands of newborn care and frequent lack of disclosure
with recent diagnosis during pregnancy.4 Especially in
resource-limited settings, there is increased potential for dis-
ruption in care as traditionally many women travel away from
home after delivery for extended stays with family, frequently
far from ARV treatment centers. In addition, resource con-
straints at the country level may preclude provision of long-
term therapy for women with higher CD4+ lymphocyte
counts after cessation of breastfeeding without sacrificing
treatment access for those who already meet WHO and the
Ministry of Health treatment criteria.
Rates of disease progression among asymptomatic
HIV-infected women during the first year after delivery have
not been well documented in resource-limited settings. Thus,
the purpose of this analysis was to assess HIV immunologic
and clinical disease progression during the first 12 months
postpartum among asymptomatic HIV-infected women with
higher CD4 counts at delivery using data from a recently
completed trial, HIV Prevention Trials Network (HPTN) 046.5
METHODS
HPTN 046 was a randomized, double-blinded placebo-
controlled trial of an extended nevirapine regimen in infants
for preventing the transmission of HIV through breastfeeding
conducted in Zimbabwe, South Africa, Uganda, and Tanzania.5
The protocol was approved by all relevant institutional review
boards and regulatory bodies; all women provided written con-
sent for themselves and their infants before enrollment.
This analysis includes women who provided informed
consent and were screened during the third trimester of
pregnancy up to 7 days postpartum whose infants were
eligible and randomized. To be eligible, women had to have
confirmed HIV-1 infection, be at least 18 years old, intend to
breastfeed, and not have any serious medical condition that
would interfere with breastfeeding or study participation.
Their infants had to be HIV uninfected at 3 days of life under
version 2.0 and at 6 weeks of age in version 3.0. Maternal
care and follow-up were the same in both versions. Maternal
ARV regimens were not provided through the study but were
available in accordance with the local standard of care, which
primarily consisted of combination ARV therapy for women
with CD4+ lymphocyte counts below 200 cells per microliter
and maternal and infant single-dose nevirapine for those with
higher CD4+ cell counts. Enrollment occurred between
February 2007 and March 2010. Infants were enrolled at 3 days
postpartum under version 2.0 and at 6 weeks postpartum in
version 3.0, but all women were enrolled by 7 days postpartum
and had study visits at delivery or within 7 days postpartum, at
2 and 6 weeks, and at 3, 6, and 12 months postpartum. At each
visit, an interim medical history and symptom-directed physical
examination were completed. Maternal HIV disease staging
was completed using the WHO staging system,6 and a complete
blood count and CD4+ lymphocyte count were obtained in
laboratories certified by the National Institute of Allergy and
Infectious Diseases (NIAID) Division of AIDS Quality Assur-
ance Program (Figs. 1 and 2)
Statistical Analyses
To assess maternal disease progression over time, we
used the Kaplan–Meier method to estimate the cumulative
proportion of mothers who progressed to 1 of 4 surrogate
disease end points at 6 and 12 months postpartum. Two of
the end points described CD4+ lymphocyte decline from base-
line at delivery: time to (1) CD4+ lymphocyte counts below
200 cells per microliter and (2) CD4+ lymphocyte counts
below 350 cells per microliter. Women were censored at the
time of ART initiation. The other 2 end points described pro-
gression to clinical AIDS or death from 6 weeks postpartum:
(3) WHO clinical stage III or IV or death and a combined end
point of (4) WHO clinical stage IV, CD4+ lymphocyte count
below 200 cells per microliter, or death. Mothers were
excluded from the analysis of the first 2 end points if they
had delivery CD4+ lymphocyte counts below 200 and 350
cells per microliter, respectively, whereas the third analysis
excluded those mothers who were stage III or IV at 6 weeks
postpartum or who had started ART before 6 weeks; and
finally, the fourth analysis excluded those mothers who were
stage IV at 6 weeks, had taken ART before six weeks, or had
CD4+ lymphocyte counts below 200 cells per microliter
before 6 weeks. For the combined end points, 3 and 4, time
to event was calculated as the minimum event time if a mother
had more than one of the qualifying outcomes. For the third
end point, women were censored at time of ARV initiation
after 6 weeks or at the last visit through 12 months postpartum
if they did not die or progress to WHO stage III or IV. For the
fourth end point, women were censored at the time of ARV
initiation after 6 weeks postpartum or at last CD4+ measure
above the threshold of 200 cells per microliter through
12 months postpartum if they did not die or progress to
WHO stage IV. Because ARV initiation is likely to be infor-
mative, a combined end point analysis was also performed
where the time to event was the minimum visit in which the
above thresholds (points 1–4) were crossed or ARV treatment
was initiated. All participants in whom the end point was not
observed were censored at their last visit time. Maternal death
incidence was calculated by dividing the number of deaths by
the total person-years through 12 months of follow-up and
stratified by CD4+ lymphocyte counts at delivery.
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RESULTS
From February 2007 to March 2010, 2025 women
enrolled into HPTN 046, including 1430 (70.7%) with CD4+
lymphocyte counts above 350 cells per microliter (Table 1).
WHO clinical staging was available at 6 weeks postpartum in
1945 women; 1855 (96%) were stage I or II. Women without
WHO clinical staging at 6 weeks had similar demographic
characteristics and baseline CD4+ lymphocyte counts compared
with those with staging (data not shown). Twenty-eight percent
of the women received triple ART regimens during pregnancy.
Other baseline characteristics are summarized in Table 1.
Maternal disease progression rates both with censoring at
ARV initiation and with ARV initiation included in the end
point are summarized in Table 2. Among women who had
CD4+ cell count results available at delivery and postpartum
sampling (Table 2), 16 (4.3%) of those with counts between
350 and 549 cells per microliter dropped to below 200 cells per
microliter by 1 year compared with 10 (1.6%) of those starting
above 549 cells per microliter (Fig. 1A). Among women who
had a CD4+ lymphocyte count between 400 and 549 cells per
microliter at delivery, 116 (37%) dropped under 350 cells per
microliter by 1 year after delivery, whereas 48 (7.4%) of those
with a CD4+ cell count of$550 cells per microliter at delivery
dropped below this threshold (Fig. 1B). When adding ARV
initiation to the end point rather than censoring, rates of the end
point of CD4+ count ,200 cells per microliter or ARV initi-
ation more than doubled for women with CD4+ counts between
350 and 549 cells per microliter but did not change appreciably
for the end point including dropping to CD4+ count below
350 cells per microliter or for those starting above a CD4+
count of 550 cells per microliter (Figure 2). For women who
started in stages I to III, 49 (4.3%) died or progressed to AIDS
based on stage IV conditions or CD4+ lymphocyte count below
200 cells per microliter by 12 months after delivery, censoring
for ARV initiation (Fig. 1C and D; Table 2). When including
ARV initiation in the end point, 88 (7.7%) met the progression
criteria. By 12 months, 83 (7.4%) women starting in clinical
stage I or II progressed to stage III or IV, whereas 159 (13.4%)
progressed to stage III or IV or initiated ARV. Of the 74
women initiating ARV by 12 months after delivery, 57
(77%) had nadir CD4+ lymphocyte counts below 200 cells
per microliter before initiation, 10 (14%) were between
200 and 300 cells per microliter, and 7 (9%) remained above
300 cells per microliter. The reasons for initiation of ARV at
higher CD4+ counts were not documented.
Twelve (1%) women who were not stage IV at their
6-week postpartum assessment developed 13 clinical stage IV
end points by 12 months after delivery. These end points
included 5 cases of extrapulmonary tuberculosis, 2 cases each
of HIV wasting (.10% weight loss plus either unexplained
FIGURE 1. Time to (A) CD4+ lymphocyte counts below 200 cells per microliter, (B) CD4+ lymphocyte counts below 350 cells per
microliter, (C) WHO clinical stage III/IV or death, and (D) WHO clinical stage IV, CD4+ count ,200 cells per microliter, or death.
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diarrhea for over 30 days or chronic weakness and unexplained
fever for over 30 days), Pneumocystis jiroveci pneumonia, and
extrapulmonary cryptococcosis, and 1 case each of central ner-
vous system toxoplasmosis and symptomatic HIV-associated
nephropathy/cardiomyopathy. Sixteen (0.8%) of enrolled women
died during the first year after delivery (see Table S1, Supple-
mental Digital Content, http://links.lww.com/QAI/A443).
Cause of death was unknown in 7 cases and had varied
causes in the other 9. Only 1 of the 9 deaths (11%) with
known causes was potentially secondary to an AIDS-
defining condition and only 2 women who died had
a CD4+ cell count below 200 cells per microliter at the visit
before death. Maternal death rates per 100 person-years strat-
ified by CD4+ lymphocyte count at delivery are shown in
Table 3. The rates of death did not differ significantly by
CD4 stratum, but number of events were low. Eleven
(68.8%) of the deaths occurred among women with CD4+
lymphocyte counts over 350 cells per microliter at the visit
before their death.
DISCUSSION
The pregnant and postpartum HIV-infected women
enrolled to this trial were representative of the women seen
at clinical research sites in sub-Saharan Africa7,8 and had a
range of CD4+ lymphocyte counts at delivery, with 70%
above 350 cells per microliter, the current threshold for initi-
ation of ARV therapy in many countries.9 Less than 5% had
stage III or IV disease at baseline, whereas 9% had CD4+
lymphocyte counts below 200 cells per microliter, suggesting
that symptoms do not reliably indicate those most in need of
ARV therapy. In addition, with the current CD4+ count
threshold of 350 cells per microliter, symptoms will not iden-
tify many of those who need therapy.
Given the standard of care existing at the sites during
the HPTN 046 trial, asymptomatic women with CD4+ lym-
phocyte counts above 350 cells per microliter did not meet
WHO or country-specific criteria for ARV therapy. Within
this context, we carefully monitored the women study partic-
ipants for disease progression to initiate treatment if needed.
This close follow-up also provided the opportunity to help
inform future treatment recommendations. Women who were
asymptomatic (WHO clinical stage I or II at baseline) had
a relatively low risk (7.4%) of progressing to symptomatic
HIV disease within 1 year postpartum, emphasizing the need
for CD4+ lymphocyte testing to target therapy for those
individuals at highest risk for disease progression in settings
where universal treatment is unaffordable. Among women
FIGURE 2. Time to ART initiation or (A) CD4+ lymphocyte counts below 200 cells per microliter, (B) CD4+ lymphocyte counts
below 350 cells per microliter, (C) WHO clinical stage III/IV or death, and (D) WHO clinical stage IV, CD4+ count ,200 cells per
microliter, or death.
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with CD4+ cell counts between 400 and 549 cells per micro-
liter at baseline, 37% dropped to below 350 cells per micro-
liter at 1 year, indicating a need for ARV therapy and
suggesting that women in this range should be offered con-
tinuation of therapy after cessation of perinatal transmission
risk. These findings are similar to data from the multicountry
MTCT-Plus Initiative, which found that women stopping
a variety of ARV regimens for prevention of perinatal trans-
mission had a 46% risk of dropping below 350 cells per
microliter by 24 months postpartum when the initial CD4+
cell count during pregnancy was 400–499 cells per microli-
ter.10 A study from Haiti found that women stopping antire-
troviral prophylaxis at delivery with a CD4+ lymphocyte
count between 350 and 499 cells per microliter dropped to
the threshold of 350 cells per microliter requiring therapy at
a median of 19 months after delivery compared with a median
of 71 months to reach this threshold among women with
CD4+ cell counts at or above 500 cells per microliter at deliv-
ery.11 These data are also consistent with a study from Brazil,
which showed that among women discontinuing ARV agents
after delivery, the group with levels between 250 and 500 cells
per microliter had a risk of progression to stage II or III events
that was 2.5 times higher than women with CD4+ counts
above 500 cells per microliter.12 The importance of CD4+
lymphocyte results for predicting progression were also
shown in a study from Kenya demonstrating that CD4 counts
and percentage during pregnancy were most predictive of
mortality over the first 2 years postpartum compared with
total lymphocyte count, hemoglobin, HIV RNA level, or
body mass index.8
Among women in the 350–550 cells per microliter
CD4+ lymphocyte group, continuation would also have ben-
efits in reduction of heterosexual transmission to discordant
partners. This conclusion is based on the results from a large
randomized trial of discordant couples, which found that
treating HIV-infected subjects with CD4+ lymphocyte counts
between 350 and 550 cells per microliter reduced linked
transmissions to partners by 96% as compared with delaying
therapy until the CD4+ lymphocyte count drops below
250 cells per microliter or symptomatic illness occurred.3
Although earlier treatment at higher CD4+ levels above
550 cells per microliter may also reduce the risk of sexual
transmission, the benefit in the group with higher counts has
not been proven. Women beginning ARVs in pregnancy with
CD4+ cell counts between 350 and 550 cells per microliter
should be counseled about the potential benefit of reduced
sexual transmission when they are considering whether or
not to continue ARVs after delivery.
Intensive counseling for adherence to the regimen must
be provided for women who choose to continue ARVs after
cessation of mother-to-child HIV transmission risk, as adher-
ence has been shown to decrease markedly once the incentive
of transmission prevention has ended. A recent meta-analysis
reported a pooled estimate of adequate adherence (.80% of
doses) of 75.7% [95% confidence interval (CI): 71.5% to
79.7%] during pregnancy compared with 53.0% (95% CI:
32.8% to 72.7%, P = 0.005) during the postpartum period.4
This study included women from a range of low-, middle-,
and high-income countries. Likewise, in several reports from
African sites, HIV-infected women were at particularly high
risk for loss to follow-up with $50% defaulting on their mater-
nal child health appointments after delivery in some studies.13–16
Travel away from home to stay with family for several months
after the birth of a child is common. In addition, many women
have not disclosed their HIV status to partners or family mem-
bers making adherence challenging, especially if residing with
relatives.17 Poor adherence increases the risk of development of
viral resistance and treatment failure.18 Concerns regarding
development of resistance may be especially important, given
the current WHO recommendations for efavirenz-based first-
line therapies that require a single mutation for resistance.9
Clearly, support for adherence and follow-up after delivery will
need to be intensified for women planning to continue ARV
agents postpartum.
In our study, women with CD4+ lymphocyte counts of
550 cells per microliter or higher had a lower risk of disease
progression with only 7.4% dropping below 350 cells per
microliter and 1.6% below 200 cells per microliter by 1 year
postpartum without ARVs. These results are consistent with
data from the MTCT-Plus Initiative, which demonstrated that
18.5% of women with initial CD4+ cell counts above 500 cells
per microliter during pregnancy progressed to counts below
350 cells per microliter by 24 months after delivery.10 The
group of women with CD4+ cell counts above 550 cells per
microliter would be expected to have a low risk of disease
progression even with discontinuation of ARVs after preg-
nancy and breastfeeding, so could discontinue therapy if





Dar es Salaam, Tanzania 218
Durban, South Africa 408
Median Age, yr (range) 27 (18–46)
Marital status
Never married/not living with partner 596 (29%)
Married 757 (37%)
Living with partner 604 (30%)
Separated/divorced/widowed 68 (3%)
Antiretrovirals received during pregnancy before delivery —
None or only intrapartum prophylaxis 583 (25%)
1 or 2 drugs 868 (43%)
3 drugs 574 (28%)
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desired. These findings underscore the utility of CD4+ lympho-
cyte testing and suggest that in this group of women, more data
are needed regarding the risks and benefits of continuing ARVs
after risk of mother-to-child transmission of HIV has passed.
There is also a need for operational research that
investigates better ways to achieve high levels of adherence
to ARV drugs among both pregnant and postpartum women
and to decrease loss to follow-up among HIV-infected pregnant
women. In areas where implementation of universal treatment
is currently not feasible for cost, supply, and logistic reasons,
targeting therapy to groups at highest risk for disease pro-
gression and transmission to their infants based on their CD4+
cell counts remains necessary. Even with implementation of
the strategy of starting lifelong therapy for all pregnant women,
CD4+ lymphocyte testing may be helpful to target women with
low CD4+ cell counts for increased support and provision of
opportunistic infection prophylaxis. Events occurring among
the postpartum women were rare but similar to those reported
in the HPTN052 study discussed above, with deaths (0.8%)
and extrapulmonary tuberculosis (0.2%) being the most fre-
quent serious events in the current study.3 Causes of death were
heterogeneous with only 2 cases occurring with proximate
CD4+ lymphocyte counts under 200 cells per microliter and
only 1 case (probable meningitis) likely AIDS defining. Other
infections (malaria and hepatitis) and comorbidities (anemia,
TABLE 2. Cumulative Rates of (A) CD4 + Cell Decline or Death Stratified by CD4+ Cell Count at Delivery and (B) Progression to
Clinical AIDS or Death at 6 and 12 months Among Women Not on Combination Antiretroviral Therapy Before Delivery
A. End Points: CD4 Decline or Death
1. Number (%) of those who drop below 200 cells/mL stratified by
baseline CD4 count
2. Number (%) of those who drop below 350 cells/mL stratified by
baseline CD4 count
Baseline Delivery Delivery Delivery Delivery
CD4 count,
cells/mL
350–549 $550 400–549 $550



















End point censored at ARV initiation
9 2.2% (0.8% to
3.7%)
6 0.9% (0.2% to
1.6%)
86 26.2% (21.3% to
30.9%)
31 4.6% (3.0% to
6.2%)
End point includes ARV initiation
20 4.9% (2.8% to
7.0%)
7 1.1% (0.3% to
1.8%)
89 27.0% (22.0% to
31.6%)




End point censored at ARV initiation
16 4.3% (2.2% to
6.3%)
10 1.6% (0.6% to
2.5%)
116 37.0% (31.3% to
42.1%)
48 7.4% (5.4% to
9.4%)
End point includes ARV initiation
39 10.3% (7.1% to
13.3%)
14 2.2% (1.1% to
3.4%)
121 38.2% (32.5% to
43.4%)
51 7.9% (5.8% to
10.0%)
B. End points: progression to clinical AIDS or death
3. Number (%) stage I to II at baseline, progress to stage III or
IV or death
4. Number (%) stage I to III at baseline, progress to stage IV, CD4,200
cells/mL or death
Baseline 6 wk postpartum 6 wk postpartum
CD4 count, cells/mL Any .200
N 1333 1285
End point reached Cumulative rate (95% CI) End point reached Cumulative rate (95% CI)
6 mo postpartum End point censored at ARV initiation
34 2.8% (1.9% to 3.7%) 26 2.2% (1.3% to 3.0%)
End point includes ARV initiation
78 6.3% (4.9% to 7.6%) 45 3.7% (2.7% to 4.8%)
12 mo postpartum End point censored at ARV initiation
83 7.4% (5.8% to 8.9%) 49 4.3% (3.2% to 5.5%)
End point includes ARV initiation
159 13.4% (11.4% to 15.3%) 88 7.7% (6.1% to 9.2%)
TABLE 3. Maternal Death Rates per 100 Person-years




per 100 person-years) 95% CI
,200 2 132.47 1.51 0.18 to 5.45
200–349 2 353.08 0.57 0.07 to 2.05
350–550 5 510.06 0.98 0.32 to 2.29
.550 7 726.90 0.96 0.39 to 1.98
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diabetes, pancreatitis, and cardiac failure) contributed to deaths,
and some of these conditions may have been ameliorated by
earlier ARV. Incomplete data on causes of death limit the
conclusions that can be drawn.
Availability of ARV therapy for women with CD4+
lymphocyte counts below 200 cells per microliter in the cur-
rent HPTN 046 study seems to have lowered the risk of death
compared with earlier studies in similar populations. The
HPTN 024 study, conducted among pregnant women in
Malawi, Zambia, and Tanzania between 2001 and 2003, at
a time when antiretroviral therapy was not widely available
in those settings, reported death rates over the first year post-
partum of 6.1 per 100 person-years among women with CD4+
lymphocyte counts below 200 cells per microliter at delivery,
1.1 per 100 person-years with CD4+ cell count of 200–500
cells per microliter, and 0.4 per 100 person-years for those with
CD4+ cell counts over 500 cells per microliter. No deaths
occurred among 331 HIV-uninfected women in the study.19
No ARV therapy was available to women after delivery in that
study. In a retrospective review of a cohort of women deliver-
ing in Malawi in 2008 who received postpartum ARV therapy
if they had WHO stage III or IV disease or CD4+ lymphocyte
count below 250 cells per microliter, the mortality rate over
18–20 months postpartum was 4.24 deaths per 100 person-
years among 173 consecutive HIV-infected women and
0 among HIV-uninfected delivering at the same sites.20
There are certain limitations to these findings including
incomplete data on causes of death and lack of longer term
follow-up. Data on the use of hormonal contraception are not
available, but unlikely to have influenced the findings, based
on data from Kenya among postpartum women that found no
differences in CD4+ cell count or HIV RNA changes with use
of hormonal contraceptives compared with no use.21 Despite
these limitations, there are also a number of strengths of the
HPTN 046 study including the large number of participants
followed in 4 African countries and excellent retention that
allowed careful monitoring of serial CD4+ lymphocyte counts
and end point ascertainment over the first year after delivery.
Because WHO and in-country guidelines in place during the
study did not recommend ARV treatment for asymptomatic
individuals with CD4+ cell counts above 200 cells per micro-
liter, these data from HIV-infected women in the first year
after delivery can help inform evolving guidelines about con-
tinuation of ARV after delivery.
Data from follow-up of the HIV-infected women
enrolled to the HPTN 046 study are informative on the risk
of disease progression among postpartum women in resource-
limited settings. Women with CD4+ lymphocyte counts
between 4000 and 550 cells per microliter in pregnancy had
a 1 in 3 risk of progressing to indications for ARV therapy
within 1 year of delivery based on the current WHO recom-
mendations. Given these findings, this group of women
should be counseled regarding the benefits of continuing
ARVs after the need for ARVs for prevention of transmission
is completed. Those who are interested in continuing ARVs
should be provided with support for disclosure to family
members, treatment adherence, and regular follow-up visits.
Pending more data on long-term outcomes from ongoing tri-
als, women with CD4+ lymphocyte counts above 550 cells
per microliter could be presented with information regarding
the potential benefits and risks of continuing ARVs and sup-
ported in their decision to stop or continue ARVs after the
indication for prevention of mother-to-child transmission of
HIV has ceased.
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